X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x - 13.9 - View Chart
P/BV x 6.1 3.9 157.6% View Chart
Dividend Yield % 0.7 0.3 216.5%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-16
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,262 125.9%   
Low Rs1,232672 183.5%   
Sales per share (Unadj.) Rs417.5270.6 154.3%  
Earnings per share (Unadj.) Rs56.324.9 226.3%  
Cash flow per share (Unadj.) Rs64.734.4 188.0%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.2 435.2%  
Book value per share (Unadj.) Rs292.9151.3 193.6%  
Shares outstanding (eoy) m119.57282.16 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.6 94.6%   
Avg P/E ratio x25.138.9 64.5%  
P/CF ratio (eoy) x21.828.1 77.6%  
Price / Book Value ratio x4.86.4 75.4%  
Dividend payout %22.68.0 280.6%   
Avg Mkt Cap Rs m168,653272,778 61.8%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m9,17113,782 66.5%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m49,91576,340 65.4%  
Other income Rs m1,645356 461.8%   
Total revenues Rs m51,56176,696 67.2%   
Gross profit Rs m8,48214,172 59.9%  
Depreciation Rs m1,0062,691 37.4%   
Interest Rs m6711,789 37.5%   
Profit before tax Rs m8,45110,048 84.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6063,028 53.0%   
Profit after tax Rs m6,7317,019 95.9%  
Gross profit margin %17.018.6 91.5%  
Effective tax rate %19.030.1 63.0%   
Net profit margin %13.59.2 146.7%  
BALANCE SHEET DATA
Current assets Rs m27,06259,096 45.8%   
Current liabilities Rs m15,32440,018 38.3%   
Net working cap to sales %23.525.0 94.1%  
Current ratio x1.81.5 119.6%  
Inventory Days Days6775 88.7%  
Debtors Days Days41119 34.6%  
Net fixed assets Rs m12,61039,075 32.3%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m34,49030,281 113.9%   
Net worth Rs m35,02742,703 82.0%   
Long term debt Rs m1,21224,873 4.9%   
Total assets Rs m54,387111,026 49.0%  
Interest coverage x13.66.6 205.6%   
Debt to equity ratio x00.6 5.9%  
Sales to assets ratio x0.90.7 133.5%   
Return on assets %13.67.9 171.6%  
Return on equity %19.216.4 116.9%  
Return on capital %24.917.5 141.9%  
Exports to sales %12.943.3 29.9%   
Imports to sales %3.17.4 41.5%   
Exports (fob) Rs m6,46133,044 19.6%   
Imports (cif) Rs m1,5405,672 27.2%   
Fx inflow Rs m6,56336,945 17.8%   
Fx outflow Rs m3,01261,066 4.9%   
Net fx Rs m3,552-24,122 -14.7%   
CASH FLOW
From Operations Rs m7,2593,449 210.5%  
From Investments Rs m1,864-8,802 -21.2%  
From Financial Activity Rs m-9,2736,986 -132.7%  
Net Cashflow Rs m-150934 -16.1%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS